IBIO
iBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
−0.81%Year over year
Reported trailing growth
- Revenue
- -75.0%
- EBITDA
- -87.6%
- EBIT
- -88.9%
- EPS
- +81.3%
- Free cash flow
- -55.3%
- Operating cash flow
- -51.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -5.1%
Three-year CAGR
- Revenue
- -33.3%
- EBITDA
- -87.6%
- EBIT
- -88.9%
- Net income
- -79.8%
- EPS
- +81.7%
- Free cash flow
- -55.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026